Bio-Techne Releases SARS-CoV-2 Multi-Antigen Serology Module For COVID-19 Research

(RTTNews) - Bio-Techne Corp. (TECH) announced that ProteinSimple, a Bio-Techne brand, released its SARS-CoV-2 Multi-Antigen Serology Module for Jess and Wes Simple Western automated western blotting systems. It is intended for research use only. The company said the serology assay accelerates COVID-19 research and vaccine development through rapid characterization of human immune response to multiple SARS-CoV-2 antigens.

The SARS-CoV-2 multi-antigen assay for Simple Western offers quantitative characterization of patient serum or plasma derived human IgG antibodies reactive against recombinant Nucleocapsid protein, S1 receptor binding domain protein, S1 subunit full length, S2 subunit full length, and Spike viral antigens within one 3-hour run.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More